SF

Su Fu

Vice President, Architect Therapeutics

San Francisco, California

Invests in

Stages:

  • Min Investment:

    $50,000.00
  • Max Investment:

    $150,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Vice President, Corporate Development

    2023

    Precision chemical editing platform for drugging tough targets. Foundational science from Yu Lab and Cravatt Lab. Series A led by ARCH.

2022 - 2023

  • Interim - Vice President, Business Development

    2022 - 2023

    RNA medicines to treat human disease in ways that were not previously possible.

2021 - 2023

  • Senior Associate

    2021 - 2023

    Build disruptive lifescience companies.

  • Market Development & Strategic Alliance

    2017 - 2021

    Early hire on the CBO/COO team, roles spanning product strategy, partnering, alliance, and IPO/financing to advance medicines against HBV, Flu, HIV, COVID-19, including Sotrovimab (EUA 2021).

2015 - 2017

  • Venture Creation, University of Chicago Innovation Fund

    2015 - 2017

    Partnered with PIs and industry executives to identify, validate, and develop promising university technologies for commercialization.

  • Associate, Investment Team

    2012 - 2015

    THL Credit is an alternative asset manager with $3 billion under management and an affiliate of Thomas H. Lee Partners.

  • Investment Banking Analyst

    2011 - 2012

    Healthcare, Leveraged Finance

2010 - 2011

  • Investment Banking Analyst

    2010 - 2011

    Global Chemicals Group - Biofuels, Renewables, Agrochemicals, and Petrochemicals.